DXVX
180400KOSDAQ기타 과학기술 서비스업47.1 / 100
Reference Date: 2026-06-10
Company InformationBased on 2025 Annual Report
Business Overview
DXVX is a biopharmaceutical company specializing in medical diagnostics, healthcare, and drug development, expanding globally through the 2022 acquisition of Hanbio Pharm and the 2023 establishment of a Chinese subsidiary. In medical diagnostics, it leverages NGS and AI-based platforms with GMP-certified facilities, while its drug development focuses on oncology therapies through partnerships with Stanford University and the acquisition of Evexis Gen. The company plans to mitigate financial risks by licensing technologies to major pharmaceutical firms.
Number of Employees
62people
Average Salary
107.4M KRW
Score Calculation Basis
Detailed Financial Score
Higher than industry avg (caution)
78.8x industry avg (excellent)
1.5x industry avg (risky)
Avg ▼20.4% (2-year basis)
Avg ▼45.7% (2-year basis)
Avg ROE -123.0% (improving, 3yr)
Detailed News Sentiment
- PositiveDXVX, '오트오브맘' 카자흐스탄 CU 입점…중앙아시아 공략 본격화
DXVX gains positive momentum through strategic expansion into Kazakhstan's CU stores with 'OatOfmom', enhancing regional market presence.
- PositiveDXVX "영국 관계사 ASCO서 OVM-200 1b상 발표…2상 준비...
DXVX announces successful clinical trial expansion for OVM-200, signaling progress towards Phase 2 and boosting global business prospects.
- Positive디엑스앤브이엑스, 'Disease X' 대응 범용 항바이러스 치료제 개...
DXVX announces significant progress towards developing a universal antiviral treatment for pandemic preparedness, supported by government research initiatives.
Detailed Momentum
52w lower range (28%)
1m -37.81% (strong drop)
Volume flat
Detailed Disclosure
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-08
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-08
- Neutral분기보고서 (2026.03)2026-05-15
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-13
- Neutral주식등의대량보유상황보고서(일반)2026-05-13